Isofol Medical

Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol's lead clinical candidate Modufolin® ([6R] 5,10-methylene tetrahydrofolate) is an endogenous folate-based biomodulator developed to increase the efficacy and decrease the side effects of chemotherapeutic agents used in the treatment of solid tumors. Isofol Medical collaborates closely with its strategic R&D partner Merck Millipore, the world's leading manufacturer of reduced folates including leucovorin and levoleucovorin.

Full Story >

stor orange

Modufolin® development

Isofol Medical's lead clinical candidate Modufolin® ([6R] 5,10-methylene tetrahydrofolate) is currently being evaluated for the treatment of rectal cancer in the clinical phase I/II study ISO-MC-091 (NCT01397305). The study evaluates the feasibilty of neoadjvant treatment with Modufolin® in combination with pemetrexed. A second clinical trial on Modufolin®, evaluating pharmacokinetic characteristics, will be launched during Q2 2012. An extensive pre-clinical safety program is ongoing and will be completed during 2012. 

Read more about the development pipeline

Newsletter

Click the link below to sign up for the Isofol newsletter and stay informed about our progress.

News & Press information

Merck and Isofol enter into an exclusive supply & license agreement
6/4/2013: Isofol Medical AB announced today that they have expanded the existing agreement and entered into a worldwide exclusive supply & license agreement with Merck KGaA and Merck & Cie (Merck) for the use of [6R]-5,10-methylenetetrahydrofolate (also known as Modufolin®) in cancer treatment.
Modufolin® shows positive pre-clinical and clinical results
3/12/2013: Isofol Medical AB today announced that it successfully has completed the first part of its preclinical safety program on Modufolin®. The GLP program performed shows no Modufolin®- related toxicity in animals. Preliminary data from two separate clinical trials also show that Modufolin® is safe when administered to patients in the dose range evaluated. The company has also recently received preliminary data which indicates that Modufolin® enables substantially greater exposure to and peak concentrations of MTHF than those obtained after administration of Levoleucovorin (L-LV).
Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden
Phone: +46 (0) 707 64 65 00 / +46 (0) 739 89 55 28 E-mail: info@isofolmedical.com